Literature DB >> 6442500

Anthrax: the disease in relation to vaccines.

P Hambleton, J A Carman, J Melling.   

Abstract

The authors trace the origins and history of anthrax and anthrax vaccines. They describe the aetiology and pathogenesis of the disease and the variety of symptoms which result from infection. The authors relate the early work performed by Pasteur, the development of existing vaccines and the efficacy of these vaccines, and predict the type of non-living vaccines which may be used to combat anthrax in the future.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6442500     DOI: 10.1016/0264-410x(84)90003-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  37 in total

1.  Search for correlates of protective immunity conferred by anthrax vaccine.

Authors:  S Reuveny; M D White; Y Y Adar; Y Kafri; Z Altboum; Y Gozes; D Kobiler; A Shafferman; B Velan
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  Identification of a protein subset of the anthrax spore immunome in humans immunized with the anthrax vaccine adsorbed preparation.

Authors:  Indira T Kudva; Robert W Griffin; Jeonifer M Garren; Stephen B Calderwood; Manohar John
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  Photoreactivation of ultraviolet-irradiated, plasmid-bearing, and plasmid-free strains of Bacillus anthracis.

Authors:  G B Knudson
Journal:  Appl Environ Microbiol       Date:  1986-09       Impact factor: 4.792

4.  Cell surface-exposed tetanus toxin fragment C produced by recombinant Bacillus anthracis protects against tetanus toxin.

Authors:  S Mesnage; M Weber-Levy; M Haustant; M Mock; A Fouet
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

5.  Expression of the Bacillus anthracis protective antigen gene by baculovirus and vaccinia virus recombinants.

Authors:  L C Iacono-Connors; C S Schmaljohn; J M Dalrymple
Journal:  Infect Immun       Date:  1990-02       Impact factor: 3.441

Review 6.  New developments in vaccines, inhibitors of anthrax toxins, and antibiotic therapeutics for Bacillus anthracis.

Authors:  J M Beierlein; A C Anderson
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

7.  Differences in susceptibility of inbred mice to Bacillus anthracis.

Authors:  S L Welkos; T J Keener; P H Gibbs
Journal:  Infect Immun       Date:  1986-03       Impact factor: 3.441

8.  Immunization studies with attenuated strains of Bacillus anthracis.

Authors:  B E Ivins; J W Ezzell; J Jemski; K W Hedlund; J D Ristroph; S H Leppla
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

9.  Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig.

Authors:  S F Little; G B Knudson
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

10.  Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity.

Authors:  P C Turnbull; M G Broster; J A Carman; R J Manchee; J Melling
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.